Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03745222
Title A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene

lung non-small cell carcinoma



Cisplatin + Etoposide + Tislelizumab

Carboplatin + Paclitaxel + Tislelizumab

Cisplatin + Etoposide

Carboplatin + Paclitaxel

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.